




RealRate

# PHARMACEUTICAL 2021

Edesa Biotech Inc.  
Rank 149 of 402



Edesa Biotech





RealRate

# PHARMACEUTICAL 2021

Edesa Biotech Inc.  
Rank 149 of 402



Edesa Biotech

The relative strengths and weaknesses of Edesa Biotech Inc. are analyzed with respect to the market average, including all of its competitors. We analyzed all variables having an effect on the Economic Capital Ratio.

The greatest strength of Edesa Biotech Inc. compared to the market average is the variable Intangible Assets, increasing the Economic Capital Ratio by 34% points. The greatest weakness of Edesa Biotech Inc. is the variable Net Income, reducing the Economic Capital Ratio by 37% points.

The company's Economic Capital Ratio, given in the ranking table, is 150%, being 103% points above the market average of 47%.

Input Variable	Value in 1000 USD
Assets, Current	8,104
Cost of Goods Sold	18
Intangible Assets	2,484
Liabilities, Current	1,530
Liabilities, Non-Current	94
Other Assets	160
Other Compr. Net Income	55
Other Expenses	0.80
Other Liabilities	30
Other Net Income	37
Other Revenues	329
Property and Equipment	15
Research and Development	3,329
Selling, General and Administrative Expense	3,383

Output Variable	Value in 1000 USD
Assets	10,762
Liabilities	1,654
Expenses	6,730
Revenues	329
Stockholders Equity	9,108
Net Income	-6,364
Comprehensive Net Income	-6,337
Economic Capital Ratio	150%